Table 1.
Patient and tumor characteristics (*significant in the 95% confidence interval)
| All n = 155 (%) |
S n = 53 (%) |
S + RT n = 58 (%) |
RT n = 44 (%) |
Chi-square test (p =) | ||
|---|---|---|---|---|---|---|
| Sex | Female | 74 (47.7) | 31(58.5) | 27 (46.6) | 16 (36.4) | 0.92 |
| Male | 81 (52.3) | 22 (41.5) | 31 (53.4) | 28 (63.6) | ||
| Age | 71 (20–99) | 69.2 (28–90) | 71.2 (49–94) | 0.397 | ||
| ECOG | 0 | 15 (9.7) | 4 (7.5) | 7 (12.1) | 4 (9.1) | < 0.001* |
| 1 | 63 (40.6) | 23 (43.4) | 29 (50.0) | 11 (25.0) | ||
| 2 | 43 (27.7) | 21 (39.6) | 14 (24.1) | 8 (18.2) | ||
| 3 | 16 (10.3) | 4 (7.5) | 8 (13.8) | 4 (9.1) | ||
| 4 | 1 (0.6) | 1 (1.9) | ||||
| Not specified | 17 (11.0) | 17 (38.6) | ||||
| Histology | Breast carcinoma | 34 (21.9) | 12 (22.6) | 16 (27.6) | 6 (13.6) | 0.071 |
| Prostate carcinoma | 28 (18.1) | 6 (11.3) | 9 (15.5) | 13 (29.5) | ||
| NSCLC | 27 (17.4) | 9 (17.0) | 7 (12.1) | 11 (25.0) | ||
| Renal cell carcinoma | 15 (9.7) | 5 (9.4) | 7 (12.1) | 3 (6.8) | ||
| Multiple myeloma | 17 (11) | 8 (15.1) | 8 (13.8) | 1 (2.3) | ||
| CUP1 adenocarcinoma | 6 (3.9) | 1 (1.9) | 4 (6.9) | 1 (2.3) | ||
| Urothelial carcinoma | 3 (1.9) | 2 (3.4) | 1 (2.3) | |||
| Esophageal carcinoma | 3 (1.9) | 1 (1.9) | 1 (1.7) | 1 (2.3) | ||
| Rectal adenocarcinoma | 3 (1.9) | 2 (3.8) | 1 (1.7) | |||
| Rhabdomyosarcoma | 2 (1.3) | 2 (3.8) | ||||
| SCLC | 2 (1.3) | 2 (4.5) | ||||
| Angiosarcoma | 2 (1.3) | 1 (1.7) | 1 (2.3) | |||
| B-cell lymphoma | 2 (1.3) | 2 (3.8) | ||||
| Colon adenocarcinoma | 2 (1.3) | 2 (3.8) | ||||
| Hepatocellular carcinoma | 2 (1.3) | 2 (4.5) | ||||
| GIST2 | 1 (0.6) | 1 (2.3) | ||||
| Thyroid carcinoma | 1 (0.6) | 1 (2.3) | ||||
| Laryngeal squamous cell carcinoma | 1 (0.6) | 1 (1.9) | ||||
| Leiomyosarcoma | 1 (0.6) | 1 (1.7) | ||||
| CLL3 | 1 (0.6) | 1 (1.9) | ||||
| Malignant melanoma | 1 (0.6) | 1 (1.7) | ||||
| Penile squamous cell carcinoma | 1 (0.6) | 1 (1.9) | ||||
| Multimodal therapy | Yes | 100 (64.5) | 26 (49.1) | 44 (75.9) | 30 (68.2) | 0.117 |
| No | 49 (31.6) | 23 (43.4) | 14 (24.1) | 12 (27.3) | ||
| Not specified | 6 (3.9) | 4 (7.5) | 2 (4.5) | |||
| Treatment indication | Medial femoral neck fracture | 37 (23.9) | 26 (49.1) | 8 (13.8) | 3 (6.8) | < 0.001* |
| Subtrochanteric femoral fracture | 17 (11.0) | 10 (18.9) | 7 (12.1) | |||
| Intertrochanteric femoral fracture | 11 (7.1) | 5 (9.4) | 6 (10.3) | |||
| Intertrochanteric metastasis/lesions | 43 (27.7) | 9 (17.0) | 20 (34.5) | 14 (31.8) | ||
| Femoral neck metastasis/lesions | 28 (18.1) | 3 (5.7) | 11 (19.0) | 14 (31.8) | ||
| Subtrochanteric metastasis/lesions | 12 (7.7) | 6 (10.3) | 6 (13.6) | |||
| Femoral head metastasis/lesions | 7 (4.5) | 7 (15.9) | ||||
| Implant |
Proximal femoral nail PFNA Gamma nail Targon® nail |
68 (43.9) 60 (38.7) 4 (2.6) 4 (2.6) |
23 (43.4) 19 (35.8) 2 (3.8) 2 (3.8) |
45 (77.6) 41 (70.7) 2 (3.4) 2 (3.4) |
0.053 | |
| Dynamic hip screw | 3 (1.9) | 1 (1.9) | 2 (3.4) | |||
| Total hip arthroplasty | 19 (34.5) | 13 (24.5) | 6 (10.3) | |||
| Hemiarthroplasty | 17 (11.0) | 12 (22.6) | 5 (8.6) | |||
| Proximal femoral replacement | 2 (1.3) | 2 (3.8) | ||||
| Mirels Score | 9,7 ± 1,1 | 9,9 ± 1,1 | 9,6 ± 1,1 | 8,1 ± 1,3 | < 0.001* |
Abbreviations 1Cancer of unknown primary, 2 Gastrointestinal stromal tumor, 3 Chronic lymphocytic leukemia, AWD = alive with disease, DOD = died of disease, DOC = died of complications, DOO = died of other circumstances